help button home button
AJRCMB
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hirasawa, Y.
Right arrow Articles by Hiwada, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hirasawa, Y.
Right arrow Articles by Hiwada, K.

Am. J. Respir. Cell Mol. Biol., Vol 17, No. 4, 10 1997, 501-507.

KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts

Y Hirasawa, N Kohno, A Yokoyama, Y Inoue, M Abe and K Hiwada
Second Department of Internal Medicine, Ehime University School of Medicine, Japan.

KL-6 in serum and bronchoalveolar lavage fluid has been reported to be a sensitive marker indicating the activity of fibrosing lung diseases. The molecule is clustered in MUC1 mucin according to the findings of immunohistochemical and cytometric studies. To elucidate the pathogenic role of KL-6 in fibrosing lung disease, we characterized its biochemical properties and examined whether purified KL-6 is chemotactic for human fibroblasts in vitro using modified Boyden chambers. Biochemical properties of purified KL-6 were similar to those of other MUC1 mucins previously reported. KL-6 promoted the migration of 5 of 5 human lung fibroblasts and 3 of 4 human skin fibroblasts. Checkerboard analysis revealed that KL-6 was chemotactic as well as chemokinetic. Though platelet-derived growth factor, fibroblast growth factor, or fibronectin were also chemotactic for fibroblasts in the experimental system, only fibronectin augmented KL-6-induced chemotaxis. These observations indicate that KL-6 is one of the chemotactic factors for most fibroblasts and that the increased KL-6 in the epithelial lining fluid in small airways may cause the intra- alveolar fibrosis in fibrosing lung diseases.


This article has been cited by other articles:


Home page
 J Intensive Care MedHome page
J. E. Levitt, M. K. Gould, L. B. Ware, and M. A. Matthay
Analytic Review: The Pathogenetic and Prognostic Value of Biologic Markers in Acute Lung Injury
J Intensive Care Med, May 1, 2009; 24(3): 151 - 167.
[Abstract] [PDF]

Home page
 Occup. Environ. Med.Home page
T Hamaguchi, K Omae, T Takebayashi, Y Kikuchi, N Yoshioka, Y Nishiwaki, A Tanaka, M Hirata, O Taguchi, and T Chonan
Exposure to hardly soluble indium compounds in ITO production and recycling plants is a new risk for interstitial lung damage
Occup. Environ. Med., January 1, 2008; 65(1): 51 - 55.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
R. Janssen, A. Kruit, J. C. Grutters, H. J. Ruven, W. B. Gerritsen, and J. M. van den Bosch
The Mucin-1 568 Adenosine to Guanine Polymorphism Influences Serum Krebs von den Lungen-6 levels
Am. J. Respir. Cell Mol. Biol., April 1, 2006; 34(4): 496 - 499.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
Q. A. Al-Salmi, J. N. Walter, G. N. Colasurdo, M. M. Sockrider, E. O. Smith, H. Takahashi, and L. L. Fan
Serum KL-6 and Surfactant Proteins A and D in Pediatric Interstitial Lung Disease
Chest, January 1, 2005; 127(1): 403 - 407.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
A. Ishizaka, T. Matsuda, K. H. Albertine, H. Koh, S. Tasaka, N. Hasegawa, N. Kohno, T. Kotani, H. Morisaki, J. Takeda, et al.
Elevation of KL-6, a lung epithelial cell marker, in plasma and epithelial lining fluid in acute respiratory distress syndrome
Am J Physiol Lung Cell Mol Physiol, June 1, 2004; 286(6): L1088 - L1094.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
R. Janssen, H. Sato, J. C. Grutters, A. Bernard, H. van Velzen-Blad, R. M. du Bois, and J. M. M. van den Bosch
Study of Clara Cell 16, KL-6, and Surfactant Protein-D in Serum as Disease Markers in Pulmonary Sarcoidosis
Chest, December 1, 2003; 124(6): 2119 - 2125.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
H. OHNISHI, A. YOKOYAMA, K. KONDO, H. HAMADA, M. ABE, K. NISHIMURA, K. HIWADA, and N. KOHNO
Comparative Study of KL-6, Surfactant Protein-A, Surfactant Protein-D, and Monocyte Chemoattractant Protein-1 as Serum Markers for Interstitial Lung Diseases
Am. J. Respir. Crit. Care Med., February 1, 2002; 165(3): 378 - 381.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Ogawa, T. Ishikawa, K. Ikeda, B. Nakata, T. Sawada, K. Ogisawa, Y. Kato, and K. Hirakawa
Evaluation of Serum KL-6, a Mucin-like Glycoprotein, as a Tumor Marker for Breast Cancer
Clin. Cancer Res., October 1, 2000; 6(10): 4069 - 4072.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
Y. HIRASAWA, N. KOHNO, A. YOKOYAMA, K. KONDO, K. HIWADA, and M. MIYAKE
Natural Autoantibody to MUC1 Is a Prognostic Indicator for Non-Small Cell Lung Cancer
Am. J. Respir. Crit. Care Med., February 1, 2000; 161(2): 589 - 594.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
C. HERMANS and A. BERNARD
Lung Epithelium-specific Proteins . Characteristics and Potential Applications as Markers
Am. J. Respir. Crit. Care Med., February 1, 1999; 159(2): 646 - 678.
[Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A. YOKOYAMA, N. KOHNO, H. HAMADA, M. SAKATANI, E. UEDA, K. KONDO, Y. HIRASAWA, and K. HIWADA
Circulating KL-6 Predicts the Outcome of Rapidly Progressive Idiopathic Pulmonary Fibrosis
Am. J. Respir. Crit. Care Med., November 1, 1998; 158(5): 1680 - 1684.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Crit. Care Med.
Copyright © 1997 American Thoracic Society. 		  ATS Coding and Billing Quarterly